# Research 1: Health Emergencies 2026

**Question**: What are the key health emergencies or emerging health priorities that multiple clinical trials are targeting right now?

**Validation Date**: 2025-01-10

---

## Clinical Trial Landscape Summary

### Total Recruiting Trials by Category

| Category | Search Query | Recruiting Trials | Key Findings |
|----------|--------------|-------------------|--------------|
| **Cancer** | cancer | **21,619** | Dominant research priority |
| **Alzheimer's/Dementia** | Alzheimer dementia | **817** | Neurodegenerative focus |
| **CAR-T/Immunotherapy** | CAR-T immunotherapy | **204** | Cancer cell therapy revolution |
| **Long COVID** | long COVID post-COVID | **161** | Emerging chronic disease |
| **Metabolic/Obesity** | diabetes obesity GLP-1 | **108** | GLP-1 transformation |
| **AI/Digital Health** | artificial intelligence digital health | **75** | Cross-cutting platform |
| **GLP-1 Agonists** | semaglutide tirzepatide | **16** | Next-generation obesity drugs |

---

## Phase 1: Cancer Trials Analysis

### Volume Statistics
```
Tool: clinicaltrials_search_trials("cancer", status="RECRUITING")
Total: 21,619 recruiting trials
```

### Representative Trial Types

| Trial ID | Title | Conditions | Interventions |
|----------|-------|------------|---------------|
| NCT:06925920 | Sacituzumab Govitecan in TNBC | Triple Negative Breast Cancer | Sacituzumab Govitecan-hziy |
| NCT:03686124 | Anti-TCR CAR-T | Refractory Solid Tumors | IMA203 + Nivolumab |
| NCT:06709223 | Cryoablation + SD-101 | Hepatocellular Carcinoma | SD-101, Durvalumab, Tremelimumab |

### Key Trends
- **Immunotherapy combinations** dominate new trial designs
- **ADC (antibody-drug conjugates)** expanding beyond breast cancer
- **CAR-T for solid tumors** emerging priority

---

## Phase 2: CAR-T/Immunotherapy Revolution

### Volume Statistics
```
Tool: clinicaltrials_search_trials("CAR-T immunotherapy", status="RECRUITING")
Total: 204 recruiting trials
```

### CAR-T Target Evolution

| Target | Indication | Example Trial |
|--------|------------|---------------|
| CD19 | B-ALL, Lymphoma | NCT:07072494 |
| CD5 | T-cell malignancies | NCT:06316856 |
| MSLN | Solid tumors | NCT:06717022 |
| EGFRvIII | Glioblastoma | NCT:06186401 |

### Key Finding
**Universal CAR-T (allogeneic)** trials emerging - reduces manufacturing time from weeks to days.

---

## Phase 3: Metabolic Epidemic (GLP-1 Transformation)

### Volume Statistics
```
Tool: clinicaltrials_search_trials("semaglutide tirzepatide", status="RECRUITING")
Total: 16 recruiting trials
```

### Next-Generation GLP-1 Agonists

| Drug | Mechanism | Trial Focus |
|------|-----------|-------------|
| **Semaglutide** | GLP-1 agonist | Weight maintenance, cardiovascular |
| **Tirzepatide** | GIP/GLP-1 dual agonist | MASLD, weight management |
| **Retatrutide** | GIP/GLP-1/Glucagon triple agonist | Obesity (Phase 3) |

### Representative Trials

| Trial ID | Title | Intervention |
|----------|-------|--------------|
| NCT:06605703 | GLP1 Transition Trial | Semaglutide/Tirzepatide step-down |
| NCT:05751720 | NAFLD/NASH + T2DM | Tirzepatide |
| NCT:06374875 | MASLD Treatment | Incretin-Based vs Surgery |

### Key Finding
**Beyond Diabetes**: GLP-1 agonists expanding to NASH/MASLD, cardiovascular protection, and even Alzheimer's disease trials.

---

## Phase 4: Alzheimer's Disease Renaissance

### Volume Statistics
```
Tool: clinicaltrials_search_trials("Alzheimer dementia", status="RECRUITING")
Total: 817 recruiting trials
```

### Therapeutic Modalities

| Modality | Example | Trial ID |
|----------|---------|----------|
| **Neuromodulation** | Combined TBS + tACS | NCT:07075770 |
| **Biomarkers** | CSF Alzheimer's biomarkers | NCT:04844060 |
| **Microbiome** | Polyphenol supplements | NCT:07226674 |
| **Imaging** | 7T MRI metabolic imaging | NCT:07202494 |

### Key Finding
**Multi-modal approaches** dominate - combining brain stimulation, lifestyle, and biomarkers rather than single-drug approaches.

---

## Phase 5: Long COVID as Emerging Priority

### Volume Statistics
```
Tool: clinicaltrials_search_trials("long COVID post-COVID", status="RECRUITING")
Total: 161 recruiting trials
```

### Research Focus Areas

| Focus | Example | Trial ID |
|-------|---------|----------|
| **Monitoring/Natural History** | Post-Covid Condition Cohort | NCT:05610436 |
| **Neuroimaging** | Neural inflammatory factors | NCT:06940609 |
| **Interventions** | Theta burst stimulation | NCT:06940609 |
| **ME/CFS Overlap** | Chronic infections | NCT:07227441 |

### Key Finding
Long COVID trials focus on **understanding mechanisms** rather than treatments - still in characterization phase.

---

## Phase 6: AI/Digital Health Platform

### Volume Statistics
```
Tool: clinicaltrials_search_trials("artificial intelligence digital health", status="RECRUITING")
Total: 75 recruiting trials
```

### AI Applications in Clinical Trials

| Application | Example | Trial ID |
|-------------|---------|----------|
| **Stroke Rehab** | AI-personalized VR | NCT:07138495 |
| **Diabetes Management** | Digital decision support | NCT:04880005 |
| **Voice Biomarkers** | Chronic disease monitoring | NCT:04848623 |

### Key Finding
AI/Digital health is a **cross-cutting platform** enabling trials across all disease areas.

---

## Knowledge Graph Structure (BioLink)

```json
{
  "nodes": [
    {"id": "CATEGORY:CANCER", "name": "Cancer Trials", "type": "biolink:ClinicalTrialCategory", "count": 21619},
    {"id": "CATEGORY:ALZHEIMER", "name": "Alzheimer/Dementia Trials", "type": "biolink:ClinicalTrialCategory", "count": 817},
    {"id": "CATEGORY:CART", "name": "CAR-T/Immunotherapy", "type": "biolink:ClinicalTrialCategory", "count": 204},
    {"id": "CATEGORY:LONGCOVID", "name": "Long COVID", "type": "biolink:ClinicalTrialCategory", "count": 161},
    {"id": "CATEGORY:METABOLIC", "name": "Metabolic/Obesity", "type": "biolink:ClinicalTrialCategory", "count": 108},
    {"id": "CATEGORY:DIGITAL", "name": "AI/Digital Health", "type": "biolink:ClinicalTrialCategory", "count": 75},
    {"id": "CHEMBL:3301600", "name": "Semaglutide", "type": "biolink:SmallMolecule"},
    {"id": "CHEMBL:4297893", "name": "Tirzepatide", "type": "biolink:SmallMolecule"},
    {"id": "INTERVENTION:CART", "name": "CAR-T Cell Therapy", "type": "biolink:Intervention"},
    {"id": "INTERVENTION:TMS", "name": "Transcranial Magnetic Stimulation", "type": "biolink:Intervention"}
  ],
  "edges": [
    {"source": "CHEMBL:3301600", "target": "CATEGORY:METABOLIC", "type": "biolink:treats"},
    {"source": "CHEMBL:4297893", "target": "CATEGORY:METABOLIC", "type": "biolink:treats"},
    {"source": "INTERVENTION:CART", "target": "CATEGORY:CANCER", "type": "biolink:investigated_in"},
    {"source": "INTERVENTION:TMS", "target": "CATEGORY:ALZHEIMER", "type": "biolink:investigated_in"}
  ]
}
```

---

## Summary: 2026 Health Emergency Priorities

### By Research Investment (Trial Count)

| Rank | Category | Trials | Trend |
|------|----------|--------|-------|
| 1 | Cancer | 21,619 | Immunotherapy + ADC combinations |
| 2 | Alzheimer's | 817 | Multi-modal neuromodulation |
| 3 | CAR-T/Immunotherapy | 204 | Universal/allogeneic expansion |
| 4 | Long COVID | 161 | Mechanistic understanding phase |
| 5 | Metabolic/Obesity | 108 | GLP-1 beyond diabetes |
| 6 | AI/Digital Health | 75 | Cross-cutting enabler |

### Key Therapeutic Transformations

1. **GLP-1 Revolution**: Expanding from diabetes to obesity, NASH, and cardiovascular protection
2. **CAR-T Evolution**: Moving from hematologic malignancies to solid tumors
3. **Neuromodulation Renaissance**: Non-invasive brain stimulation for Alzheimer's
4. **Long COVID Emergence**: New chronic disease category requiring novel endpoints

### MCP Tools Used

- `clinicaltrials_search_trials` - Trial discovery by disease/intervention
- All searches filtered by `status="RECRUITING"` for active research

---

## Comparison to Catalog Predictions

| Category | Catalog Estimate | Validated Count | Status |
|----------|------------------|-----------------|--------|
| Cancer | 21,584 | 21,619 | Confirmed (+0.2%) |
| Metabolic | 5,552 | 108* | Different query scope |
| Long COVID | 186 | 161 | Confirmed (-13%) |
| Alzheimer's | 617 | 817 | Higher (+32%) |
| AI/Digital | 932 | 75* | Different query scope |

*Note: Narrow query terms used; broader searches would yield higher counts.
